Clinical Utility of Amyloid Imaging in Differential Diagnosis of Atypical/Unclear Dementias and Its Impact on Caregivers (P5.186)

Objective: To study the clinical utility of amyloid imaging in atypical dementia cases and its impact on Background: Alzheimer9s disease (AD) is characterized by accumulation of fibrillary amyloid plaques in the brain. Several studies have explored the role of positron emission tomography (PET) using amyloid biomarkers which allow in vivo visualization of plaques to distinguish AD pathology from other forms of protein accumulations leading to dementia. However, very few authors have investigated the role of amyloid imaging in the differential diagnosis of atypical/unclear cases that is complex dementia syndromes where even a comprehensive investigation yields no clear diagnosis. Moreover, no studies have investigated its impact on caregivers and their perception of the process. Methods: Using a novel amyloid tracer (NAV4694), we scanned 30 patients with an atypical/unclear dementia syndrome as determined by an experienced behavioral neurologist from a tertiary care center. All patients had a full work-up (i.e., clinical, blood tests, neuropsychological evaluation, structural and functional imaging) yet no certain diagnosis. Amyloid-PETs were either positive or negative based on qualitative and quantitative reads by two independent readers. questionnaire was given to the treating neurologist to determine whether amyloid imaging allowed a more accurate diagnosis and changed treatment plans. Caregivers were met one month after revelation of diagnosis and completed a questionnaire followed by a standardized interview. Results: A statistically significant increase in confidence levels amongst physicians who ordered amyloid imaging in such cases was found. Revelation of diagnosis to caregivers was associated with better acceptance of the disease as well as a clearer view of future challenges. Conclusions: This study suggests that amyloid imaging is useful in the differential diagnosis of atypical/unclear dementias, and has a positive impact on caregivers. Amyloid-PET is indicated in the investigation of complex, atypical/unclear dementing disorders. Disclosure: Dr. Laforce has nothing to disclose. Dr. Bensaidane has nothing to disclose. Dr. Bouchard has nothing to disclose. Dr. Fortin has nothing to disclose. Dr. Houde has nothing to disclose. Dr. Rosa Neto has nothing to disclose. Dr. Poulin has received personal compensation for activities with Actelion as a speaker. Dr. Verret has received research support from Genentech, Servier, Hoffman-Laroche, and Lilly. Dr. Soucy has nothing to disclose. Dr. Beauregard has nothing to disclose.